Literature DB >> 6944252

Significance of cytogenetic abnormalities in acute leukemias.

H M Golomb, J D Rowley.   

Abstract

Chromosome abnormalities of a clonal nature have been found in approximately 50 per cent of the patients with acute nonlymphocytic leukemia and acute lymphocytic leukemia. Patients with acute myeloblastic leukemia (M1 and M2) with only abnormal metaphases have the worst prognosis among patients with acute nonlymphocytic leukemia, whereas patients with acute myeloblastic leukemia (M1 and M2) with only normal metaphases have the best prognosis. Specific abnormalities include a t(8;21) in approximately 8 per cent of the patients with acute nonlymphocytic leukemia and a t(15;17) in approximately 50 per cent of the patients with either hypergranular (M3) or microgranular (M3 variant) promyelocytic leukemia. In patients who develop acute leukemia after cytotoxic or radiation therapy for a previous malignant disease, clonal chromosome abnormalities are almost always present.

Entities:  

Mesh:

Year:  1981        PMID: 6944252     DOI: 10.1016/s0046-8177(81)80065-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Cytogenetic study in acute myeloid leukaemia using peripheral blood samples sent by post.

Authors:  Y S Li; F G Hayhoe
Journal:  J Clin Pathol       Date:  1982-08       Impact factor: 3.411

Review 2.  Karyotypic progression in human tumors.

Authors:  S R Wolman
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

3.  Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity.

Authors:  M Peeters; A Poon
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

4.  Human chromosome analysis in 24 cases of primary carcinoma of the large intestine: contribution of the G-banding technique.

Authors:  M H Couturier-Turpin; D Couturier; P Nepveux; A Louvel; Y Chapuis; J Guerre
Journal:  Br J Cancer       Date:  1982-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.